Insmed Incorporated
Bridgewater, NJ
- UEI
- GLE1HZQ47JW6
- CAGE
- 4HSZ2
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- Bridgewater, NJ 08807, USA
- Website
- insmed.com
- Employees
- 251-1K
- Estimated annual revenue
- $50M-$100M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | -$29,404 |
| FY2025 | $111,159 |
| FY2024 | -$26,775 |
| FY2023 | $53,550 |
Contract vehicles
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Grant awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Development of a novel pro tool for use in clinical trials to measure symptoms in patients with non-cystic fibrosis… | FDA Office of Acquisition and Grant Services | $1,690,567 |
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| United Therapeutics Corp | Silver Spring, MD | 325412 Pharmaceutical Preparation Manufacturing |
| Centocor Ortho Biotech Inc. | Horsham, PA | 325414 Biological Product (except Diagnostic) Manufacturing |
| Bristol-Myers Squibb Company | Lawrence Township, NJ | 325412 Pharmaceutical Preparation Manufacturing |
| Recordati Rare Diseases Inc. | Bridgewater, NJ | 325411 Medicinal and Botanical Manufacturing |
| Daiichi Pharmaceutical Corp | Bernards, NJ | 325412 Pharmaceutical Preparation Manufacturing |
About the company
Insmed Incorporated, a for-profit biopharmaceutical manufacturer headquartered in Bridgewater, New Jersey, sells specialized pharmaceutical products — including ARIKAYCE (liposomal amikacin inhalation) for nontuberculous mycobacterial lung infections, BELZUTIFAN (WELIREG) for renal cell carcinoma, and amikacin antibiotic formulations — to the Department of Veterans Affairs as a prime contractor operating exclusively under full-and-open (non-set-aside) vehicles.
Insmed's federal footprint consists entirely of prime awards across GSA pharmaceutical supply schedules and blanket purchase agreements; the vendor has no subcontract exposure and does not compete under SBA set-asides. The company operates under two parent vehicles with the VA: a $24.15 million multiple-award Federal Supply Schedule (65 IB, Drugs, Pharmaceuticals, and Hematology Related Products) running through May 31, 2029, and a $49,323.45 single-award Blanket Purchase Agreement for ARIKAYCE running through June 14, 2027. Both vehicles carry no set-aside designation. Delivery orders flow from these parent vehicles at approximately $10,105 per order; representative awards include a $10,105.40 delivery order from Veterans Integrated Service Network 5 for ARIKAYCE (amikacin) 590mg/8.4ml in June 2025, a $10,105.41 order from VISN 5 for BELZUTIFAN (WELIREG) 40 mg in February 2025, and a $26,775.24 emergency amikacin order from Veterans Integrated Service Network 22 in July 2023. All performance occurs at Insmed's Carrollton, Texas facility.
Customer concentration is entirely within Veterans Affairs. Fourteen awards (82% of the portfolio) are distributed across Veterans Integrated Service Network 12 (3 awards, $28.4 million combined potential value), the National Acquisition Center (3 awards, $10 million), VISN 5 (5 awards, $72 thousand), VISN 2 (2 awards, $31 thousand), and VISN 20 (1 award, $10 thousand). The disparity between award count and dollar concentration reflects the structure of the FSS and BPA vehicles: multiple small delivery orders execute against high-ceiling parent vehicles, with VISN 12's role as the nominal contracting entity on the $24.15 million FSS driving the potential-value ranking despite VISN 5's higher order frequency.
Activity has accelerated recently: one award in 2020, one in 2023, two in 2024, and five in 2025. Combined potential value across all seventeen awards is $46.1 million, but combined obligated dollars total only $1.8 million (4% of potential), a gap reflecting typical GSA schedule behavior where ceiling values far exceed near-term execution. The vendor's classification is straightforward — pharmaceutical preparation manufacturing under NAICS 325412 and Drugs and Biologicals under PSC, with sixteen of seventeen awards concentrated in those categories.
Quick answers
Is Insmed Incorporated registered in SAM.gov?
Yes. Insmed Incorporated's SAM.gov registration is active through May 18, 2027.
Which contract vehicles does Insmed Incorporated hold?
Insmed Incorporated holds a place on 1 federal contract vehicle: FSS-61-IB.
How much has Insmed Incorporated received in federal contracts?
Federal contracts obligated $111,159 to Insmed Incorporated in fiscal year 2025 and $108,531 in fiscal years 2023 through 2027.
What is Insmed Incorporated's most recent federal award?
Insmed Incorporated's most recent federal contract award is Rezdiffra 80 MG (36C24526N0641), from Veterans Integrated Service Network 5 (VHA), on June 10, 2026.
On GovTribe
See Insmed Incorporated's full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors